文献速递胸部肿瘤放疗

III期非小细胞肺癌加速大分割放疗联合同步化疗的1期研究:CALGB 31102

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-01-31

该1期研究探讨不可手术III期非小细胞肺癌患者接受加速大分割放疗联合同期化疗的安全性,总放疗剂量固定为60 Gy,逐队列减少分次数的方案中最大耐受剂量定义为队列2(60 Gy,2.5 Gy/次)。21例可评估患者中3例发生5级毒性(队列2咯血1例,队列3咯血1例、肺炎1例),中位总生存19.3个月(95%CI 9.3-34.0个月),中位无进展生存12.2个月(95%CI 6.1-22.5个月)。作者结论认为仅能实现适度大分割,进一步研究可能有助于更好定义治疗指数。

要点

  • 最大耐受剂量定义为队列2:60 Gy,2.5 Gy/次。
  • 21例可评估患者中3例发生5级毒性:队列2咯血1例,队列3咯血1例、肺炎1例。
  • 中位总生存19.3个月(95%CI 9.3-34.0个月),中位无进展生存12.2个月(95%CI 6.1-22.5个月)。

核心结论

  • 由于长期毒性,仅能实现适度大分割。
  • 最大耐受剂量为60 Gy,2.5 Gy/次,允许以比常规治疗少20%的治疗次数完成放疗。
  • 进一步研究加速大分割放疗可能有助于更好定义治疗指数。

研究设计与样本

  • 1期研究,纳入不可手术III期非小细胞肺癌患者,总放疗剂量固定为60 Gy,逐队列减少每日一次分次数:队列1为60 Gy/27次,队列2为60 Gy/24次,队列3为60 Gy/22次,队列4为60 Gy/20次。
  • 同期化疗为每周卡铂AUC 2和紫杉醇45 mg/m2;巩固治疗为卡铂AUC 6和紫杉醇200 mg/m2,×2周期(原文此处写作 every weeks,未写明间隔周数)。
  • 最大耐受剂量定义:每队列6例患者中,≤2例发生≥3级毒性且≤1例发生≥4级毒性;2012年7月至2014年5月共入组22例,其中21例可评估。

主要发现

  • 5级毒性发生于3例患者:队列2中1例(咯血),队列3中2例(咯血、肺炎)。
  • 发生5级毒性的时间分别为治疗开始后9个月、6个月和9个月。
  • 存活患者中位随访时间23.0个月(范围7.6-30.6个月),中位总生存19.3个月(95%CI 9.3-34.0个月),中位无进展生存12.2个月(95%CI 6.1-22.5个月)。
  • 最大耐受剂量由队列2定义(60 Gy,2.5 Gy/次)。

关键数值与推荐

  • 最大耐受剂量:队列2为60 Gy,2.5 Gy/次。
  • 剂量限制性毒性阈值:每队列6例患者中,≤2例发生≥3级毒性且≤1例发生≥4级毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 由于长期毒性,仅能实现适度大分割。
  • 进一步研究加速大分割放疗可能有助于更好定义治疗指数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the safety of accelerated hypofractionated radiation therapy (AHRT) with concurrent chemotherapy (CT) for inoperable stage III non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: The primary objectives were to define the maximally tolerable course of accelerated radiation therapy and to describe toxicities of therapy. Total radiation therapy remained at 60 Gy. The number of once-daily fractions in each successive cohort was reduced as follows: cohort 1, 60 Gy in 27 fractions; cohort 2, 60 Gy in 24 fractions; cohort 3, 60 Gy in 22 fractions; and cohort 4, 60 Gy in 20 fractions. Concurrent treatment consisted of weekly carboplatin area under the curve (AUC) 2 and paclitaxel 45 mg/m2. Consolidation treatment consisted of carboplatin AUC 6 and paclitaxel 200 mg/m2 every weeks × 2 cycles. Maximum tolerated dose: Of 6 patients/cohort, ≤2 patients experienced grade ≥3 toxicity, and ≤1 patient experienced grade ≥4 toxicity. RESULTS: 22 patients were accrued; of those, 21 patients were evaluable between July 2012 and May 2014. Grade 5 toxicity occurred in 3 patients: 1 patient in cohort 2 (hemoptysis), 2 patients in cohort 3 (hemoptysis, pneumonitis). The maximum tolerated dose (MTD) was defined by cohort 2 (60 Gy in 2.5 Gy/fraction). Time to grade 5 toxicity was 9 months, 6 months, and 9 months after the start of treatment. The median follow-up time was 23.0 months (range, 7.6-30.6 months) in living patients, the median overall survival was 19.3 months (95% confidence interval [CI] 9.3-34.0 months), and the median progression-free survival was 12.2 months (95% CI 6.1-22.5 months). CONCLUSIONS: Only modest hypofractionation was achievable as a result of long-term toxicities. Nevertheless, the MTD of 60 Gy given at 2.5 Gy/fraction allows completion of RT in 20% fewer treatments than conventional therapy. Further investigation of AHRT may help to better define the therapeutic index.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Urbanic JJ, Wang X, Bogart JA, et al. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). Int J Radiat Oncol Biol Phys. 2018. PMID: 29487024. doi:10.1016/j.ijrobp.2018.01.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。